S-1
Raltitrexed
Meng QiuPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Raltitrexed cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltitrexed Meng Qiu | Phase 2 | BB |
Adebrelimab Meng Qiu | Phase 2 | CCC |
Fruquintinib Meng Qiu | Phase 2 | CCC |
Regorafenib China Medical University, China | Phase 1/2 | CCC |
Same molecule, other indications
S-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →